Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2024-02-05 00:00:00 ET · period of report 2024-02-01 · accession 0001725160-24-000026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-05 | 2024-02-01 | ZNTL | Blackwell Kimberly | CEO, Dir | A - Grant | $0.00 | +250.0K | 504.8K | +98% | $0 |
| D | 2024-02-05 | 2024-02-01 | ZNTL | Blackwell Kimberly | CEO, Dir | F - Tax | $11.69 | -20.7K | 484.1K | -4% | -$241.5K |
| D | 2024-02-05 | 2024-02-01 | ZNTL | Blackwell Kimberly | CEO, Dir | A - Grant | $0.00 | +250.0K | 250.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-01 | A | A | 250,000 | $0.00 | 504,800 | D | — | — | (F1) Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer. |
| 2 | Common | Common Stock | 2024-02-01 | F | D | 20,655 | $11.69 | 484,145 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-02-01 | A | A | 250,000 | $0.00 | 250,000 | D | $11.69 · — to 2034-01-31 | 250,000 Common Stock | (F3) The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. |